See more : Homerun Resources Inc. (AKAVF) Income Statement Analysis – Financial Results
Complete financial analysis of NRx Pharmaceuticals, Inc. (NRXP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NRx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aigan Co.,Ltd. (9854.T) Income Statement Analysis – Financial Results
- PTT Public Company Limited (PTT-R.BK) Income Statement Analysis – Financial Results
- Aurora Spine Corporation (ASAPF) Income Statement Analysis – Financial Results
- Zhejiang Weixing New Building Materials Co., Ltd. (002372.SZ) Income Statement Analysis – Financial Results
- Kingswood Holdings Limited (KWG.L) Income Statement Analysis – Financial Results
NRx Pharmaceuticals, Inc. (NRXP)
About NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 4.00K | 2.00K | 907.41K | 0.00 | 1.01M | 0.00 |
| Gross Profit | -5.00K | -4.00K | -2.00K | -907.41K | 0.00 | -1.01M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.37M | 17.03M | 20.26M | 10.63M | 3.50K | 0.00 | 0.00 |
| General & Administrative | 14.22M | 27.37M | 74.94M | 11.44M | 2.77K | 0.00 | 0.00 |
| Selling & Marketing | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.21M | 27.37M | 74.94M | 11.44M | 2.77K | 1.01M | 0.00 |
| Other Expenses | 0.00 | -505.00K | -771.00K | -10.16M | 713.19K | 1.01M | 0.00 |
| Operating Expenses | 27.58M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
| Cost & Expenses | 27.59M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
| Interest Income | 494.00K | 249.00K | 18.00 | 56.00 | 1.21M | 1.09M | 0.00 |
| Interest Expense | 120.00K | 0.00 | 18.00K | 56.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.00K | 4.00K | 2.00K | 2.00K | 0.86 | 1.09M | 52.52K |
| EBITDA | -30.03M | -39.75M | -93.04M | -51.72M | -713.19K | 82.41K | -105.04K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -27.59M | -44.40M | -115.80M | -51.39M | -6.26K | -1.01M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.57M | 4.58M | 22.73M | -39.88M | 1.21M | 1.09M | -105.03K |
| Income Before Tax | -30.16M | -39.82M | -93.06M | -51.78M | 492.63K | 82.41K | -105.03K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.00K | -4.58M | -21.35M | -39.43M | 84.21K | 16.31K | 0.00 |
| Net Income | -30.15M | -35.24M | -71.72M | -12.35M | 408.43K | 66.10K | -105.03K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| EPS Diluted | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| Weighted Avg Shares Out | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
| Weighted Avg Shares Out (Dil) | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
Formulation based on prior patents by NRx founder Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration Company expects Composition of Matter patent protection Company previously executed joint development agreement with US manufacturer of...
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Data transferred for independent statistical analysis Top-line data expected in April 2024 RADNOR, Pa. , April 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has achieved...
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
NRx Pharmaceuticals (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 4th
DELL, NRXP, STEP, TCOM and PARAA have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend -- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share...
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces...
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Common Stock Will Begin Trading on Split-Adjusted Basis on April 2, 2024 RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to effect a...
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
RADNOR, Pa., March 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on...
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
RADNOR, Pa. , March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present...
Source: https://incomestatements.info
Category: Stock Reports